Page 5 - Sohini Das

Cancer drug shortage: Drugmaker Naprod seeks one-time price hike

Says higher import duties, regulatory hurdles have made chemo drugs' production unviable

Drug companies seek NPPA price revision for cancer drugs amid shortage

Oncology drugmaker says soaring platinum prices, higher import duties and lengthy import approvals have made production financially unviable, worsening shortages of key chemotherapy medicines

M&M bets beyond tractors to drive farm mechanisation and rural enterprise

Expands focus beyond tractors into harvesters, seed drills and telematics-led services

Services, digital business emerge as drivers of TaMo CV arm's earnings

Iveco seen as technology and global expansion platform; EVs and hydrogen remain central to future strategy

Tata Motors CV ready for next phase, but challenges ahead: N Chandrasekaran

Tata Motors chairman says the commercial vehicles business is poised for growth after the demerger, with technology, innovation and global expansion driving strategy

Centre's ₹9,585-cr green scheme for NCR may boost CV replacement demand

The two-year programme aims to replace over 2 lakh ageing trucks and buses across Delhi-NCR through interest subsidies, tax waivers and manufacturer discounts

Ceat bets on CAMSO to drive next phase of off-highway tyre growth

The tyre maker expects tracks and developed markets such as North America and Europe to power growth as access to additional CAMSO categories expands

Wockhardt eyes $1.5 bn peak sales from Zaynich, targets US launch by yr-end

Novel antibiotic to be launched in India around the same time; company to commercialise product on its own in US

Maruti's mini-car sales up 147% in April-May on easing constraints

Maruti Suzuki reports a sharp rebound in mini-car sales as production constraints ease, while rising fuel prices drive stronger demand for CNG-powered vehicles

Luxury sedans hold ground in SUV era as premium buyers stay loyal

Nearly three in 10 luxury vehicles sold in India are sedans, with Audi, BMW and Mercedes-Benz each deriving about 40 per cent of India sales from the body style

Biocon's next chapter: A leadership team built for the next decade

The team put together by the firm's founder may be just what the next decade demands

MedTherapy bets on low-cost CAR-T manufacturing with Noida CDMO push

Boston-headquartered MedTherapy Biotech is expanding its India manufacturing footprint while preparing clinical trials for a lymphoma-focused CAR-T therapy with Cipla

Crisil stress test reveals sectors facing risk, and those less affected

Crisil states 22 of the 34 sectors stress-tested could see operating profitability decline by over 10 per cent as companies may not be able to fully pass on higher costs to consumers immediately

Mounting costs turn the heat on India Inc amid West Asia conflict

Firms diversify sourcing, redraw playbook, increase prices to tide over crisis

Indian drugmakers deepen US bets despite decline in pharma exports

Indian pharmaceutical companies are investing in specialty drugs, biosimilars and local manufacturing in the US despite a near 10 per cent fall in exports in FY26

West Asia conflict: EV cost edge sharpens amid rising fuel prices

Petrol, diesel have seen cumulative hike of ₹5 per litre in May

CCI says hospitals not automatic monopolies over admitted patients

Max hospitals, Indraprastha among chains involved in series of 12 orders

NephroPlus sharpens global dialysis push as overseas business grows

NephroPlus said overseas markets now contribute nearly 42 per cent of revenue as the dialysis provider expands globally through acquisitions, PPP projects and clinic additions

India could emerge as $7 bn MedTech contract manufacturing hub by 2035

India's overall MedTech opportunity could expand more than fourfold to $83-89 billion by 2035, driven by rising domestic demand, exports and contract manufacturing

Top carmakers remain bullish on FY27 domestic demand amid global risks

Auto companies have not cut back on capex and are planning new launches, even as they remain cautious about margins amid input costs and supply-chain risks